At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients
In Brief
A Phase 2 clinical trial evaluating Tauroursodeoxycholic Acid and Placebo oral capsule for Progressive Multiple Sclerosis. Completed, enrolled 59 participants across 1 site.
Detailed Summary
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS). Participants will also be assessed for an impact of the bile acid on their immune system and gut microbiome. Half of the participants will receive the bile acid tauroursodeoxycholic acid (TUDCA) and half will receive placebo. The investigators believe participants who take TUDCA will have normalization of blood bile acid levels, a normalization of abnormal immune response and a normalization of the gut microbiome.
Study Details
Timeline
Interventions
Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
Participants will be given four capsules of the placebo twice daily.